Daniel Van Langenberg

23PUBLICATIONS
22CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Traditional, complementary and integrative medicine not elsewhere classifiedRegenerative medicine (incl. stem cells)Condensed matter characterisation technique developmentCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|Feb 28, 2025
Comparing Long-Term Infliximab Persistence Following a Switch to a Biosimilar in Patients With Inflammatory Bowel Disease: No Cause for Concern.

Paulina Suo, Ashish Srinivasan, Lena Thin

|Sep 05, 2024
6-Thioguanine nucleotide levels are associated with infliximab but not adalimumab levels in inflammatory bowel disease patients on combination therapy.

Natalie Yu, Tanya Lee, Daniel Tassone

|Mar 25, 2024
Letter: Thioguanine, an under-utilised option in inflammatory bowel disease? Authors' reply.

Abhinav Vasudevan, Danny Con, Daniel R van Langenberg

|Feb 24, 2024
Editorial: Towards optimal thiopurine therapy for inflammatory bowel disease-authors' reply.

Abhinav Vasudevan, Danny Con, Daniel R van Langenberg

|Jan 01, 2024
Utility of panenteric capsule endoscopy for the detection of small-bowel Crohn's disease in patients with a normal magnetic resonance enterography: A prospective observational pilot study.

Anuj Bohra, Diana Lewis, Jonathan P Segal

|Dec 14, 2023
Clinical trial: Combination allopurinol-thiopurine versus standard thiopurine in patients with IBD escalating to immunomodulators (the DECIDER study).

Abhinav Vasudevan, Danny Con, Peter De Cruz

Pageof 4

Frequent Collaborators

9 joint publications

Abhinav Vasudevan

5 joint publications

Ashish Srinivasan

5 joint publications

Danny Con

3 joint publications

Steven Nicolaides